22 results
Thumbnail

D1.284 - Eosinophilic Esophagitis Before and After Milk Oral Immunotherapy in Children with Food Allergy: A Case Series Including the Eosinophil-to-Lymphocyte Ratio

Thumbnail

D1.283 - Endolysosomal degradation of major peanut allergens revealed distinct degradation kinetics and T cell epitope regions

Thumbnail

D1.286 - Allergenic Protein Profiling in a Patient with Long-standing Nut-Induced Anaphylaxis

Thumbnail

D1.287 - Polysensitization to Seed Storage Proteins, LTPs and Profilin in a Patient With Anaphylaxis After Consumption of Pesto Sauce

Thumbnail

D2.191 - Tolerogenic Immune Shifts Following PQ Grass 27600 SU Treatment in Seasonal Allergic Rhinitis

Thumbnail

D2.181 - Managing asthma and allergies during the Russo-Ukrainian war: The damage assessment

Thumbnail

D2.183 - Differential Sensitization to Goat and Sheep Milk with Partial Tolerance to Cow’s Milk

Thumbnail

D2.184 - Sensitization profile to vespid venom: limitations in clinical practice

Thumbnail

D2.187 - Are Component-Based Skin Tests Reliable? Correlation between Skin Prick Testing and Specific IgE to Der p 1, Der p 2 and Der p 23

Thumbnail

D2.188 - Spectrum of Sensitization to Respiratory Allergens in Patients in the Republic of Kazakhstan

Thumbnail

D2.190 - Evaluation of a commercially available Birch Pollen Extract for its suitability in Nasal Allergen Challenges: Feasibility and Dose-Response Assessment

Thumbnail

D2.192 - Comparison of the Multiplex ALEX Method and Single-Plex ImmunoCAP Method in the Diagnosis of Seasonal Allergic Rhinitis in Adults Caused by Birch Pollen

Thumbnail

D2.193 - Real-World Effectiveness of Allergen Immunotherapy in Polysensitized Patients: A Retrospective Study of 260 Cases

Thumbnail

D2.195 - AIT prescription drivers: a cluster analysis of data from the CHOICE survey

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child